Switch theme
Sign up to access all valuation multiples
Biomm SA is engaged in biotechnological processes for the production of active pharmaceutical ingredients and other industrial purposes, such as enzymes used in the production of Biofuels.The Company is patented for insulin production.The company develops processes for the production of insulin and other biotech products, as well as processes for other industrial applications, such as enzymes that are used in the production of biofuels.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomm has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Biomm achieved revenue of $24.9M and an EBITDA of -$9.3M.
Biomm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $20.6M | $24.9M | XXX | XXX | XXX |
| Gross Profit | $2.8M | $4.1M | XXX | XXX | XXX |
| Gross Margin | 14% | 16% | XXX | XXX | XXX |
| EBITDA | -$9.8M | -$9.3M | XXX | XXX | XXX |
| EBITDA Margin | -48% | -37% | XXX | XXX | XXX |
| Net Profit | -$16.1M | -$14.1M | XXX | XXX | XXX |
| Net Margin | -78% | -57% | XXX | XXX | XXX |
| Net Debt | $16.8M | $22.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Biomm's stock price is BRL 10 (or $2).
Biomm has current market cap of BRL 1.2B (or $211M), and EV of BRL 1.2B (or $207M).
See Biomm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $207M | $211M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Biomm has market cap of $211M and EV of $207M.
Biomm's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Biomm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Biomm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $207M | XXX | XXX | XXX |
| EV/Revenue | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | -22.3x | XXX | XXX | XXX |
| P/E | -15.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -10.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBiomm's NTM/LTM revenue growth is n/a
Biomm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Biomm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Biomm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Biomm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -37% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 35% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 69% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomm acquired XXX companies to date.
Last acquisition by Biomm was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Biomm founded? | Biomm was founded in 2002. |
| Where is Biomm headquartered? | Biomm is headquartered in Brazil. |
| Is Biomm publicy listed? | Yes, Biomm is a public company listed on BVMF. |
| What is the stock symbol of Biomm? | Biomm trades under BIOM3 ticker. |
| When did Biomm go public? | Biomm went public in 2000. |
| Who are competitors of Biomm? | Similar companies to Biomm include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Biomm? | Biomm's current market cap is $211M |
| What is the current revenue growth of Biomm? | Biomm revenue growth between 2023 and 2024 was 21%. |
| Is Biomm profitable? | Yes, Biomm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
